| Literature DB >> 36203781 |
Nahia Goñi1,2, Itziar Martínez-Soroa1,2, Oliver Ibarrondo3, Mikel Azkargorta4, Felix Elortza4, David J Galarreta5, Arantxa Acera6,7.
Abstract
Purpose: Keratoconus (KC) is a corneal ectasia characterized by structural changes, resulting in progressive thinning and biomechanical weakening that can lead to worsening visual acuity due to irregular astigmatism. Corneal collagen Crosslinking (CXL) and Intracorneal Ring Segment (ICRS) are widely used treatments in KC disease, but the alterations they cause in biomechanical mediators are still poorly understood. The aim of this study was to analyze the tear proteome profile before and after treatments to identify biomarkers altered by surgery. Materials and methods: An observational, prospective, case-control pilot study was conducted, analyzing tear samples from KC patients by nano-liquid chromatography-mass spectrometry (nLC-MS/MS). Data are available via ProteomeXchange with identifier PXD035655. Patients with KC who underwent ICRS surgery (n = 4), CXL (n = 4), and healthy subjects (Ctrl, n = 4) were included in this study. Clinical parameters were measured and tear samples were collected before and 18 months after surgery. Proteins with ≥2 expression change and p-value < 0.05 between groups and times were selected to study their role in post-operative corneal changes.Entities:
Keywords: biomarker; crosslinking; intracorneal ring segment; keratoconus; tear film
Year: 2022 PMID: 36203781 PMCID: PMC9531826 DOI: 10.3389/fmed.2022.944504
Source DB: PubMed Journal: Front Med (Lausanne) ISSN: 2296-858X
Comparison of results after treatment with baseline values.
| Ctrl | ICRS | CXL | |||||
| Variable | Baseline | Baseline | 18 month | Baseline | 18 month | ||
| UDVA (logMAR) | −0.04 (IRQ: 0.29) | 0.73 (IQR: 0.30) | 0.60 (IQR: 0.36) | 0.486 | 0.55 (IQR: 0.27) | 0.61 (IQR: 0.16) | 1.000 |
| CDVA (logMAR) | −0.13 (IRQ: 0.10) | 0.22 (IQR: 0.21) | 0.10 (IQR: 0.07) | 0.234 | 0.28 (IQR: 0.17) | 0.12 (IQR: 0.07) | 0.309 |
| SE (D) | 0.32 (IRQ: 0.65) | −4.31 (IQR: 2.32) | −3.25 (IQR: 2.75) | 0.800 | −7.75 (IQR: 4.00) | −6.77 (IQR: 3.60) | 0.800 |
| K1 (D) | 42.35 (IRQ: 0.93) | 47.55 (IQR: 3.25) | 45.95 (IQR: 2.47) | 0.486 | 46.80 (IQR: 1.85) | 46.75 (IQR: 2.60) | 0.686 |
| K2 (D) | 43.25 (IRQ: 0.88) | 54.50 (IQR: 7.10) | 49.85 (IQR: 6.92) | 0.343 | 51.50 (IQR: 1.90) | 50.85 (IQR: 1.25) | 0.886 |
| Kmax (D) | 43.60 (IRQ: 0.95) | 62.00 (IQR: 6.55) | 58.00 (IQR: 2.27) | 0.200 | 61.40 (IQR: 6.20) | 62.05 (IQR: 9.05) | 1.000 |
| Mean-K (D) | 42.80 (IRQ: 0.83) | 53.45 (IQR: 3.25) | 47.65 (IQR: 4.93) | 0.110 | 48.35 (IQR: 1.20) | 48.50 (IQR: 1.30) | 0.657 |
| MCT (μ) | 558.00 (IRQ: 58.25) | 429.50 (IQR: 6.00) | 435.50 (IQR: 6.25) | 0.486 | 451.00 (IQR: 24.00) | 436.00 (IQR: 40.00) | 0.886 |
| OSM (mOsm/L) | 275.50 (IRQ: 3.50) | 304.00 (IQR: 0.00) | 290.50 (IQR: 9.25) | 0.100 | 304.50 (IQR: 9.75) | 313.50 (IQR: 8.50) | 0.057 |
| OSDI | 2.00 (IRQ: 1.00) | 6.50 (IQR: 10.0) | 1.00 (IQR: 3.25) | 0.301 | 18.00 (IQR: 12.50) | 16.50 (IQR: 13.75) | 0.772 |
| TBUT (sec) | 11.50 (IRQ: 3.75) | 13.50 (IQR: 5.50) | 16.00 (IQR: 2.50) | 0.306 | 10.00 (IQR: 2.50) | 13.50 (IQR: 7.50) | 0.661 |
| SCH (mm) | 13.50 (IRQ: 4.00) | 14.50 (IQR: 2.75) | 10.50 (IQR: 8.25) | 0.561 | 12.00 (IQR: 16.00) | 10.50 (IQR: 15.25) | 0.663 |
Values are expressed as median and interquartile range (IQR).
UDVA, uncorrected distance visual acuity (logMAR); CDVA, corrected distance visual acuity (logMAR); SE, spherical equivalent (diopters); K1, flat keratometry (diopters); K2, steep keratometry (diopters); Kmax, maximum keratometry (diopters); Mean-K, mean keratometry (diopters); MCT, minimal corneal thickness (μ); OSM, tear osmolarity (mOsm/L); OSDI, ocular surface disease index; TBUT, tear break up time (seconds); SCH, Schirmer’s test (mm). P < 0.05 show statistically significant differences.
FIGURE 1Volcano map of protein expression was performed for the pairwise comparison of the three groups; ICRS vs. Ctrl (A), CXL vs. Ctrl (B), and CXL vs. ICRS (C), differentiating between the two time periods considered (Baseline and 18 months).
Changes between surgical techniques and control group by time period and expression type.
| Period | Group | Entry name | Description | Fold | |
| Basal | ICRS/Ctrl | ASC-1 | Activating signal cointegrator 1 complex subunit 3 | 3.26 | 0.006 |
| KV118 | Ig kappa chain V-I region WEA | 2.81 | 0.048 | ||
| DSP | Desmoplakin | 2.32 | 0.043 | ||
| CALR | Calreticulin | 0.20 | 0.003 | ||
| AT1A4 | Sodium/potassium-transporting ATPase subunit alpha-4 | 0.18 | 0.005 | ||
| PROL-4 | Proline-rich protein 4 | 0.16 | 0.030 | ||
| APOBEC-3A | DNA dC → dU-editing enzyme APOBEC 3A | 0.12 | 0.011 | ||
| CXL/Ctrl | DSP | Desmoplakin | 5.13 | 0.001 | |
| PRG2 | Bone marrow proteoglycan | 3.77 | 0.014 | ||
| ALS | Insulin-like growth factor-binding protein complex acid | 3.55 | 0.028 | ||
| ABCA1 | ATP-binding cassette sub-family A member 1 | 2.58 | 0.005 | ||
| AMY1 | Alpha-amylase 1 | 0.41 | 0.019 | ||
| PROM1 | Prominin-1 | 0.39 | 0.047 | ||
| GLU2B | Glucosidase 2 subunit beta | 0.28 | 0.030 | ||
| MUC5B | Mucin-5B | 0.26 | 0.031 | ||
| CXL/ICRS | AKP13 | A-kinase anchor protein 13 | 26.98 | 0.019 | |
| ALS | Insulin-like growth factor-binding protein complex acid | 3.87 | 0.012 | ||
| CATD | Cathepsin D | 3.31 | 0.017 | ||
| PEDF | Pigment epithelium-derived factor | 2.13 | 0.005 | ||
| ASCC3 | Activating signal cointegrator 1 complex subunit 3 | 0.43 | 0.037 | ||
| CALU | Calumenin | 0.41 | 0.013 | ||
| OLFM4 | Olfactomedin-4 | 0.27 | 0.006 | ||
| GLU2B | Glucosidase 2 subunit beta | 0.25 | 0.004 | ||
| 18 months | ICRS/Ctrl | CO7 | Complement component C7 | 11.23 | 0.027 |
| MDHM | Malate dehydrogenase mitochondrial | 10.83 | 0.005 | ||
| ASAH1 | Acid ceramidase | 7.38 | 0.031 | ||
| ELNE | Neutrophil elastase | 6.83 | 0.018 | ||
| MUC5B | Mucin-5B | 0.37 | 0.039 | ||
| PEDF | Pigment epithelium-derived factor | 0.35 | 0.034 | ||
| CXL/Ctrl | CO7 | Complement component C7 | 7.97 | 0.006 | |
| HPTR | Haptoglobin-related protein | 6.70 | 0.005 | ||
| TFF1 | Trefoil factor 1 | 6.14 | 0.047 | ||
| ZA2G | Zinc-alpha-2-glycoprotein | 3.19 | 0.001 | ||
| CAP1 | Adenylyl cyclase-associated protein 1 | 0.20 | 0.001 | ||
| LV211 | Ig lambda chain V-II region NIG-84 | 0.15 | 0.038 | ||
| IGHG2 | Ig gamma-2 chain C region | 0.11 | 0.007 | ||
| MUC5B | Mucin-5B | 0.11 | 0.004 | ||
| CXL/ICRS | AKP13 | A-kinase anchor protein 13 | 13.40 | 0.05 | |
| APOE | Apolipoprotein E | 7.76 | 0.046 | ||
| K1C16 | Keratin type I cytoskeletal 16 | 6.09 | 0.014 | ||
| HPTR | Haptoglobin-related protein | 4.12 | 0.004 | ||
| ZA2G | Zinc-alpha-2-glycoprotein | 2.64 | 0.000 | ||
| CO1 | Complement factor I | 0.19 | 0.001 | ||
| MMP9 | Matrix metalloproteinase-9 | 0.10 | 0.019 | ||
| ELNE | Neutrophil elastase | 0.08 | 0.031 | ||
| CAP1 | Adenylyl cyclase-associated protein 1 | 0.07 | 0.003 |
P < 0.05 show statistically significant differences.
FIGURE 2Most of the differentially expressed proteins could be localized to the extracellular and intracellular compartments once the biological context and functional annotation analyses. As a result, deregulated proteins were seen to be involved in different biological processes.
FIGURE 3Volcano map of protein expression for the pairwise comparison of the two time periods (Baseline and 18 months), differentiating between groups; Ctrl (A), ICRS (B), and CXL (C).
Proteins with the most relevant expression changes before and after the intervention by surgery type.
| Group | Entry name | Description | Fold | |
| ICRS | LV001 | Ig lambda chain V region 4A | 4.19 | 0.035 |
| HS90B | Heat shock protein HSP 90-beta | 4.09 | 0.004 | |
| GYLG | Glycogenin-1 | 3.44 | 0.008 | |
| KV113 | Ig kappa chain V-I region Lay | 2.74 | 0.048 | |
| LV301 | Ig lambda chain V-III region SH | 2.32 | 0.003 | |
| CATD | Cathepsin D | 2.30 | 0.038 | |
| DESP | Desmoplakin | 2.07 | 0.031 | |
| LC1L1 | Putative lipocalin 1-like protein 1 | 0.48 | 0.001 | |
| AK1A1 | Alcohol dehydrogenase [NADP(+)] | 0.36 | 0.009 | |
| CXL | K1C9 | Keratin type I cytoskeletal 9 | 4.03 | 0.012 |
| TPM2 | Tropomyosin beta chain | 3.15 | 0.039 | |
| C1R | Complement C1r subcomponent | 3.02 | 0.040 | |
| ZA2G | Zinc-alpha-2-glycoprotein | 2.98 | 0.003 | |
| SLPI | Antileukoproteinase | 2.47 | 0.014 | |
| K1C10 | Keratin type I cytoskeletal 10 | 2.30 | 0.032 | |
| CY24B | Cytochrome b-245 heavy chain | 2.27 | 0.020 | |
| AHNK | Neuroblast differentiation-associated protein | 0.45 | 0.003 | |
| ML12A | Myosin regulatory light chain 12A | 0.25 | 0.020 | |
| F11 | Protein F11 | 0.22 | 0.042 | |
| MYH14 | Myosin-14 | 0.21 | 0.033 | |
| KV206 | Ig kappa chain V-II region RPMI 6410 | 0.21 | 0.046 | |
| SSPO | SCO-spondin | 0.20 | 0.035 | |
| PROF1 | Profilin-1 | 0.19 | 0.045 | |
| PGAM1 | Phosphoglycerate mutase 1 | 0.19 | 0.007 |
P < 0.05 show statistically significant differences.